News Column

Investigators from Goethe-University Target Gene Therapy (Oral gene therapy for hemophilia B using chitosan-formulated FIX mutants)

July 24, 2014



By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Research findings on Biotechnology are discussed in a new report. According to news reporting originating in Frankfurt, Germany, by NewsRx journalists, research stated, "Oral gene delivery of non-viral vectors is an attractive strategy to achieve transgene expression. Although expected efficacy from non-viral delivery systems is relatively low, repeated vector administration is possible and may help to obtain durable transgene expression in a therapeutic range."

The news reporters obtained a quote from the research from Goethe-University, "To test the principle feasibility of using factor (F) IX variants with improved function combined with an optimized oral delivery system in hemophilia B (HB) mice. FIX modifications were introduced by site-directed mutagenesis into plasmid- or minicircle-based expression cassettes. Vectors were formulated as chitosan nanoparticles for oral delivery to HB mice. Protection of vector DNA in nanoparticle constructs and transfection efficiency were characterized. HB mice received eGFP-formulated chitosan nanoparticles to confirm gene transfer in vivo. FIX expression, phenotype correction and the potential of nanoparticles to induce immunotolerance (ITI) against exogenous FIX were evaluated after repeated oral administration. Transfection of HEK 293T cells or livers of FIX-knockout mice with nanoparticles resulted in GFP or functional FIX expression. Oral administration of FIX mutants resulted in exclusive FIX expression in the small intestine, as confirmed by RT-PCR and fluorescence staining. HB mice demonstrated transient FIX expression reaching >14% of normal activity and partial phenotype correction after oral delivery of FIX mutants with high specific activity and improved tissue release. The feasibility of oral, non-viral delivery of FIX was established and improved by bioengineered FIX proteins and optimized vectors."

According to the news reporters, the research concluded: "Thus, these data might point the way for development of a clinically applicable oral gene transfer strategy for hemophilia B."

For more information on this research see: Oral gene therapy for hemophilia B using chitosan-formulated FIX mutants. Journal of Thrombosis and Haemostasis, 2014;12(6):932-942. Journal of Thrombosis and Haemostasis can be contacted at: Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell - www.wiley.com/; Journal of Thrombosis and Haemostasis - onlinelibrary.wiley.com/journal/10.1111/(ISSN)1538-7836)

Our news correspondents report that additional information may be obtained by contacting P. Quade-Lyssy, Goethe Univ Frankfurt, Dept. of Pediat 3, D-60054 Frankfurt, Germany. Additional authors for this research include P. Milanov, D. Abriss, C. Ungerer, C. Konigs, E. Seifried and J. Schuttrumpf (see also Biotechnology).

Keywords for this news article include: Biotechnology, Europe, Germany, Frankfurt, Hematology, Gene Therapy, Hemophilia A, Nanoparticle, Bioengineering, Nanotechnology, Emerging Technologies

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Gene Therapy Weekly


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters